MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Let’s Talk Medtech

Dexcom Is Sitting on Top of the World Right Now and Here’s Why

Image courtesy of Dexcom IMG_2022-6-17-143429.jpg
There’s no denying Dexcom’s meteoric rise over the last few years. Kevin Sayer, Dexcom CEO, joins this episode of Let’s Talk Medtech to discuss how the company is reaching new heights.

What is 2022 looking like for Dexcom so far? Kevin Sayer, Dexcom CEO spoke with Let’s Talk Medtech shortly after the 82nd Scientific Sessions of the American Diabetes Association about some of the company’s accomplishments and how its setting itself apart in the CGM space.

To date, the company has an impressive track record.

In March, the San Diego, CA-based company won CE Mark for the G7 continuous glucose monitoring system. The firm also won breakthrough device designation to take its CGM technology into the hospitals.  

In May, the company launched Dexcom One in the UK. The device is a more affordable and accessible option for people with diabetes. Dexcom One also provides the company a way to expand into geographies where it doesn't already have infrastructure or distribution partnerships in place, and where there may not be reimbursement or where reimbursement would be difficult.

Dexcom’s biggest achievement in 2022 will be once the G7 is approved by FDA. The technology is one of the most-anticipated devices in medtech.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.